Cooperative Agreement U01CA292771
Award Date
8/9/24
Completion Date
7/31/29
Dollars Obligated
$592K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Evanston, IL 60208, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel point-of-care nucleic acid amplification test (NAAT) for the diagnosis of hepatitis C virus (HCV) infection using whole blood samples. The $1,483,048 award, spanning from July 2024 to May 2029, supports the University of Washington's research to create a low-complexity, rapid NAAT device that can...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel point-of-care (POC) assay to rapidly quantify hepatitis C virus (HCV) viral load and assess associated liver damage. The $876,400 award will enable researchers at the University of Notre Dame to integrate virus ultrafiltration and Janus microparticle detection technologies into a 30-minute,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $884,453 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Brigham & Women's Hospital Inc. in Boston, MA. The grant aims to develop a rapid, cost-effective point-of-care diagnostic test for detecting hepatitis C virus (HCV) infections, which pose a significant global health challenge. The project seeks to create a highly sensitive and specific HCV antigen testing platform...
The National Cancer Institute (NCI) awarded a $646,186 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Nord Bio Inc. to develop and evaluate a non-invasive assay to detect and monitor tumor-derived cell-free DNA (cfDNA) levels in saliva for head and neck squamous cell carcinoma (HNSCC) patients. The project aims to compare the sensitivity of the saliva-based cfDNA assay to plasma/blood-based cfDNA testing, and to develop the experimental and computational methodology for...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund a hybrid type III effectiveness-implementation trial to test best practices for deploying a "screen and treat" approach to cervical cancer screening utilizing self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The 5-year, $643,363 project aims to improve access to affordable HPV testing and promote...
This $585,943 Cooperative Agreement awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a low-cost, rapid, and easy-to-use point-of-care HPV DNA test to improve cervical cancer screening in Mozambique. The project will: 1) Adapt an extraction-free, multiplexed isothermal nucleic acid amplification assay to detect high-risk HPV types on an integrated nucleic acid amplification and lateral flow detection platform called NATFLOW; 2)...
This $421,744 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a peptide multimer for early detection of hepatocellular carcinoma (HCC). The Regents of the University of Michigan will lead this 5-year research project to identify new HCC-specific molecular targets using single-cell RNA sequencing and create a multivalent peptide-based imaging agent. The multimer will be labeled for magnetic resonance...
The National Cancer Institute (NCI) awarded a $436,472 R21 project grant to Cedars-Sinai Medical Center under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The objective is to investigate the performance of novel circulating biomarker digital scores for evaluating treatment response in hepatocellular carcinoma (HCC) patients. The research leverages two technologies - an HCC extracellular vesicle digital scoring assay and the GALAD serum protein-based scoring system - to...
This $634,061 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment of liver cancer, or hepatocellular carcinoma (HCC), during HIV infection. The key objectives are to: 1) Characterize how TAPDC reprogram the HCC tumor immune microenvironment, and how HIV infection affects TAPDC and the tumor immune microenvironment; 2) Define how TAPDC...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $483,194 to the Research Institute at Nationwide Children's Hospital (RINCH) to define the protective CD4+ T cell responses against the hepatitis C virus (HCV). The research aims to characterize the CD4+ T cell signatures that support effective CD8+ T cell immunity against HCV, using historical blood and...